EP3847191A4 - Conditionally active chimeric antigen receptors for modified t-cells - Google Patents

Conditionally active chimeric antigen receptors for modified t-cells Download PDF

Info

Publication number
EP3847191A4
EP3847191A4 EP19856976.6A EP19856976A EP3847191A4 EP 3847191 A4 EP3847191 A4 EP 3847191A4 EP 19856976 A EP19856976 A EP 19856976A EP 3847191 A4 EP3847191 A4 EP 3847191A4
Authority
EP
European Patent Office
Prior art keywords
cells
modified
chimeric antigen
antigen receptors
conditionally active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19856976.6A
Other languages
German (de)
French (fr)
Other versions
EP3847191A2 (en
Inventor
Jay M. Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/125,302 external-priority patent/US11111288B2/en
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of EP3847191A2 publication Critical patent/EP3847191A2/en
Publication of EP3847191A4 publication Critical patent/EP3847191A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
EP19856976.6A 2018-09-07 2019-08-23 Conditionally active chimeric antigen receptors for modified t-cells Withdrawn EP3847191A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/125,302 US11111288B2 (en) 2014-08-28 2018-09-07 Conditionally active chimeric antigen receptors for modified t-cells
PCT/US2019/047848 WO2020050993A2 (en) 2018-09-07 2019-08-23 Conditionally active chimeric antigen receptors for modified t-cells

Publications (2)

Publication Number Publication Date
EP3847191A2 EP3847191A2 (en) 2021-07-14
EP3847191A4 true EP3847191A4 (en) 2022-06-08

Family

ID=69721682

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19856976.6A Withdrawn EP3847191A4 (en) 2018-09-07 2019-08-23 Conditionally active chimeric antigen receptors for modified t-cells

Country Status (5)

Country Link
EP (1) EP3847191A4 (en)
JP (1) JP7432250B2 (en)
CN (1) CN112823166A (en)
AU (1) AU2019334864A1 (en)
WO (1) WO2020050993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021247525A1 (en) * 2020-06-02 2021-12-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Dual egfr-muc1 chimeric antigen receptor t cells
WO2022187182A1 (en) * 2021-03-02 2022-09-09 The Trustees Of The University Of Pennsylvania Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes
CN115477704B (en) * 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on LOX1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033331A1 (en) * 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
WO2018136570A1 (en) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Chimeric antigen receptors against axl or ror2 and methods of use thereof
US20190010220A1 (en) * 2014-08-28 2019-01-10 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
LT2956175T (en) * 2013-02-15 2017-12-11 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
MX2017002805A (en) 2014-09-03 2017-12-20 Bioatla Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts.
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
WO2018044619A1 (en) 2016-08-31 2018-03-08 Bioatla, Llc Conditionally active polypeptides and methods of generating them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033331A1 (en) * 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
US20190010220A1 (en) * 2014-08-28 2019-01-10 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
WO2018136570A1 (en) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Chimeric antigen receptors against axl or ror2 and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHO JANG HWAN ET AL: "Engineering Axl specific CAR and SynNotch receptor for cancer therapy", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 March 2018 (2018-03-01), pages 3846, XP055916559, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-018-22252-6.pdf> DOI: 10.1038/s41598-018-22252-6 *
NERRETER T ET AL: "ROR2 is a novel target for CAR T cells in breast cancer", ONCOLOGY RESEARCH AND TREATMENT20170901S. KARGER AGNLD, vol. 40, no. 3, 1 September 2017 (2017-09-01), Oncology Research and Treatment20170901S. Karger AGnld, pages 130, XP055916567, ISSN: 2296-5262 *
WEI JING ET AL: "A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers", CELLULAR IMMUNOLOGY, vol. 331, 1 September 2018 (2018-09-01), US, pages 49 - 58, XP055879132, ISSN: 0008-8749, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0008874918301618/pdfft?md5=49bb4e1e019ba14d9de246f49a3be59d&pid=1-s2.0-S0008874918301618-main.pdf> DOI: 10.1016/j.cellimm.2018.05.004 *

Also Published As

Publication number Publication date
EP3847191A2 (en) 2021-07-14
AU2019334864A1 (en) 2021-03-11
JP2021536256A (en) 2021-12-27
WO2020050993A2 (en) 2020-03-12
JP7432250B2 (en) 2024-02-16
TW202024124A (en) 2020-07-01
WO2020050993A3 (en) 2020-04-16
CN112823166A (en) 2021-05-18

Similar Documents

Publication Publication Date Title
EP3341406A4 (en) Conditionally active chimeric antigen receptors for modified t-cells
EP3580212A4 (en) Regulating chimeric antigen receptors
EP3820484A4 (en) Ror-1 specific chimeric antigen receptors and uses thereof
EP3528851A4 (en) Cereblon-based heterodimerizable chimeric antigen receptors
EP3755722A4 (en) Cd83-binding chimeric antigen receptors
EP3784699A4 (en) Optimized anti-tl1a antibodies
EP3827025A4 (en) Gd2-based chimeric antigen receptor and application thereof
EP3806857A4 (en) Cd79b chimeric antigen receptors
EP3752197A4 (en) Nkg2d chimeric antigen receptors
EP3806903A4 (en) Cd79a chimeric antigen receptors
EP3797122A4 (en) Anti-ror antibody constructs
EP3849598A4 (en) Anti-trem-2 agonist antibodies
IL285587A (en) Hypoxia-responsive chimeric antigen receptors
EP3802615A4 (en) Muc16 specific chimeric antigen receptors and uses thereof
EP3720882A4 (en) T-cells comprising two different chimeric antigen receptors and uses thereof
EP3604344A4 (en) Chimeric antigen receptor
EP3919515A4 (en) Chimeric antigen receptor and use thereof
EP3847191A4 (en) Conditionally active chimeric antigen receptors for modified t-cells
EP3688143A4 (en) Pd1-specific chimeric antigen receptor as an immunotherapy
AU2019361253A1 (en) Anti-synuclein antibodies
EP3765078A4 (en) Anti-gucy2c chimeric antigen receptor compositions and methods
EP3920952A4 (en) Chimeric cytokine receptors
IL285909A (en) Anti-bcma chimeric antigen receptors
EP4013798A4 (en) Chimeric antigen receptors and uses thereof
EP3852779A4 (en) Anti-klrg1 antibodies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210322

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016180000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20220510

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20220503BHEP

Ipc: C07K 14/735 20060101ALI20220503BHEP

Ipc: A61K 35/17 20150101ALI20220503BHEP

Ipc: C07K 14/705 20060101ALI20220503BHEP

Ipc: A61K 39/395 20060101ALI20220503BHEP

Ipc: C07K 14/725 20060101ALI20220503BHEP

Ipc: C07K 16/28 20060101AFI20220503BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221210